Relevance of multidrug resistance in the age of targeted therapy

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Molecularly targeted therapies show promise but face resistance mechanisms.
• ATP-binding cassette (ABC) transporters, including P-glycoprotein (P-gp) and ABCG2, mediate multidrug resistance (MDR) by reducing intracellular drug concentrations.
• Overexpression and mutations in drug transporters contribute to treatment failure in cancer.

Purpose of the Study:

• To explore P-glycoprotein (P-gp) as a molecular target in multidrug-resistant cancers.
• To investigate the potential of MDR1-inverse compounds to selectively eliminate P-gp-overexpressing cancer cells.
• To assess the impact of targeting P-gp on cancer stem cells responsible for tumor recurrence.

Main Methods:

• Analysis of the role of ABC transporters in regulating intracellular drug concentrations.
• Proposal of P-gp as a therapeutic target in MDR cancer.
• Exploitation of the hypersensitivity of MDR cells to MDR1-inverse compounds.

Main Results:

• P-gp is identified as a key regulator of intracellular drug concentrations and a biomarker of drug resistance.
• MDR1-inverse compounds demonstrate selective elimination of P-gp-overexpressing cancer cells.
• Targeting P-gp offers a strategy to reduce tumor burden and eliminate cancer stem cells.

Conclusions:

• P-glycoprotein (P-gp) should be considered a molecular target for overcoming multidrug resistance (MDR) in cancer.
• MDR1-inverse compounds can selectively target and eliminate cancer cells and cancer stem cells that overexpress P-gp.
• This approach holds potential for reducing tumor burden and preventing cancer recurrence.